These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21546955)

  • 21. Useful plants of dermatology. VIII. The false hellebore (Veratrum californicum).
    McFerren MA
    J Am Acad Dermatol; 2006 Apr; 54(4):718-20. PubMed ID: 16546599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
    Kudchadkar R; Lewis K; Gonzalez R
    Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 24. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 25. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 26. Antitumor Activity of Isosteroidal Alkaloids from the Plants in the Genus Veratrum and Fritillaria.
    Shang Y; Du Q; Liu S; Staadler M; Wang S; Wang D
    Curr Protein Pept Sci; 2018; 19(3):302-310. PubMed ID: 28059041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma.
    Jacobsen AA; Kydd AR; Strasswimmer J
    J Am Acad Dermatol; 2017 Apr; 76(4):767-768. PubMed ID: 28325399
    [No Abstract]   [Full Text] [Related]  

  • 28. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
    Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
    Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.
    Xu FG; Ma QY; Wang Z
    Cancer Lett; 2009 Oct; 283(2):119-24. PubMed ID: 19232458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal cell carcinoma, Hedgehog signaling, and targeted therapeutics: the long and winding road.
    Wong SY; Dlugosz AA
    J Invest Dermatol; 2014 Oct; 134(e1):E18-22. PubMed ID: 25302468
    [No Abstract]   [Full Text] [Related]  

  • 31. Hedgehog hopes lifted by approval... and stung by failure.
    Allison M
    Nat Biotechnol; 2012 Mar; 30(3):203. PubMed ID: 22398601
    [No Abstract]   [Full Text] [Related]  

  • 32. M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition.
    Xu X; Ye J; Huang C; Yan Y; Li J
    Toxicol Appl Pharmacol; 2019 Feb; 364():77-82. PubMed ID: 30578886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 34. Basal cell carcinoma: hedgehog pathway inhibitors and beyond.
    Walls B
    Cutis; 2013 Jun; 91(6):E1-4. PubMed ID: 23837158
    [No Abstract]   [Full Text] [Related]  

  • 35. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging treatments and signaling pathway inhibitors.
    Tang JY; Marghoob AA
    Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S14-8. PubMed ID: 22177102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
    Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
    N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hedgehog Pathway Inhibitors for Periocular Basal Cell Carcinoma.
    Ashraf DC; Vagefi MR
    Int Ophthalmol Clin; 2020; 60(2):13-30. PubMed ID: 32205649
    [No Abstract]   [Full Text] [Related]  

  • 39. [New therapeutic target of breast cancer].
    Kubo M; Kuroki S; Tanaka M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():142-7. PubMed ID: 17679196
    [No Abstract]   [Full Text] [Related]  

  • 40. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.